Literature DB >> 16109597

Matrix metalloproteinase-13 and membrane type-1 matrix metalloproteinase in peritoneal fluid of women with endometriosis.

Piotr Laudanski1, Jacek Szamatowicz, Przymyslaw Ramel.   

Abstract

OBJECTIVE: It is becoming more and more evident that different types of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are involved in the pathogenesis of endometriosis. The aim of the present study was to measure levels of the active forms of MMP-13 and membrane type-1 matrix metalloproteinase (MT1-MMP)/MMP-14 as well as TIMP-2 in the peritoneal fluid of women with endometriosis. STUDY
DESIGN: We determined the levels of the active forms MMP-13 and MT1-MMP/MMP-14 as well as TIMP-2 in the peritoneal fluid of 20 women with endometriosis and 18 controls by different types of enzyme-linked immunosorbent assay.
RESULTS: We found that the concentrations (mean +/- standard deviation) of total active MMP-13 and endogenous active MT1-MMP/MMP-14 in the peritoneal fluid of patients with endometriosis were 1.69 +/- 0.67 and 3.12 +/- 1.07 ng/ml, respectively. In control women the corresponding values were 3.02 +/- 0.43 and 4.45 +/- 1.03 ng/ml. The differences were statistically significant (p < 0.0001 and p < 0.0004 for MMP-13 and MMP-14, respectively). Levels of TIMP-2 did not differ significantly.
CONCLUSIONS: Decreased concentrations of active MMP-13 and MT1-MMP/MMP-14 may imply that the proteolytic activity of the peritoneal milieu of women with endometriosis is disturbed, which may have implications in the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16109597     DOI: 10.1080/09513590500154043

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  7 in total

Review 1.  Malignant Transformation and Associated Biomarkers of Ovarian Endometriosis: A Narrative Review.

Authors:  Liudmila M Mikhaleva; Aleksandr I Davydov; Olga I Patsap; Elizaveta V Mikhaylenko; Vladimir N Nikolenko; Margarita E Neganova; Sergey G Klochkov; Siva G Somasundaram; Cecil E Kirkland; Gjumrakch Aliev
Journal:  Adv Ther       Date:  2020-05-08       Impact factor: 3.845

Review 2.  The bimodal role of matrix metalloproteinases and their inhibitors in etiology and pathogenesis of endometriosis (Review).

Authors:  Magdalenia Bałkowiec; Radosław B Maksym; Paweł K Włodarski
Journal:  Mol Med Rep       Date:  2018-07-23       Impact factor: 2.952

Review 3.  The Role of Matrix Metalloproteinases in Endometriosis: A Potential Target.

Authors:  Junya Ke; Jiangfeng Ye; Mingqing Li; Zhiling Zhu
Journal:  Biomolecules       Date:  2021-11-22

4.  The Role of Cadherin 12 (CDH12) in the Peritoneal Fluid among Patients with Endometriosis and Endometriosis-Related Infertility.

Authors:  Ksawery Goławski; Robert Soczewica; Joanna Kacperczyk-Bartnik; Grzegorz Mańka; Mariusz Kiecka; Michał Lipa; Damian Warzecha; Robert Spaczyński; Piotr Piekarski; Beata Banaszewska; Artur Jakimiuk; Tadeusz Issat; Wojciech Rokita; Jakub Młodawski; Maria Szubert; Piotr Sieroszewski; Grzegorz Raba; Kamil Szczupak; Tomasz Kluz; Marek Kluza; Mirosław Wielgoś; Ewa Koc-Żórawska; Marcin Żórawski; Piotr Laudański
Journal:  Int J Environ Res Public Health       Date:  2022-09-14       Impact factor: 4.614

5.  Profiling of Selected MicroRNAs in Proliferative Eutopic Endometrium of Women with Ovarian Endometriosis.

Authors:  P Laudanski; R Charkiewicz; A Tolwinska; J Szamatowicz; A Charkiewicz; J Niklinski
Journal:  Biomed Res Int       Date:  2015-08-20       Impact factor: 3.411

6.  MicroRNAs expression profiling of eutopic proliferative endometrium in women with ovarian endometriosis.

Authors:  Piotr Laudanski; Radoslaw Charkiewicz; Mariusz Kuzmicki; Jacek Szamatowicz; Alicja Charkiewicz; Jacek Niklinski
Journal:  Reprod Biol Endocrinol       Date:  2013-08-15       Impact factor: 5.211

Review 7.  Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis.

Authors:  Sun-Wei Guo
Journal:  Reprod Med Biol       Date:  2018-08-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.